Benzinga··PrnewswireInhibrx Narrows Q1 Loss to $33.4M as Cash Position Strengthens on $75M Debt Deal
Inhibrx reported improved Q1 2026 losses and bolstered cash reserves through debt financing while advancing key oncology programs toward critical milestones.
INBXcolorectal cancernet loss